RE: New Presentation5 Sep 2018 12:21
slides mention about market opportunity of $2.8Bn with ABSSI and $1.7Bn with HABP but there are other active antibiotics mentioned(slide 13) for ABSSI - Daptomycin, LineZolid, Ceftaroline along with Vancomycin...don't know if these other active antibiotics are in trial phase or already in the market?
Based on market opportunity and with NDA acceptance, this definitely is way too undervalued. Looks like any acquisitions and JVs would take place only after approval but we have seen pharma companies being acquired in trial phase itself and MTFB is in a much better position. I think MTFB may have had some offers and BOD would have rejected it. Until there is any news on deal, SP may stay in the current range and till the FDA approval as well! I'm happy to wait for another 6 months as I don't think there is going to be any bad news until FDA approval so no reason for SP to go down further. AMP share sale could take this down but we have seen this sprung back to current range quickly. ATB